

XOLAIR REFERRAL FORM

PATIENT INFORMATION	PRESCRIBER INFORMATION
Patient Name _____	Prescriber Name _____ DEA# _____
Address _____	NPI# _____ Tax ID _____
City _____ State _____ Zip _____	Practice Name _____
Home Phone _____ Cell _____	Address _____ Suite _____
DOB _____ SSN _____	City _____ State _____ Zip _____
Drug Allergies: _____ <input type="checkbox"/> Male <input type="checkbox"/> Female	Office Phone _____ Fax _____
Patient Weight: _____ Height: _____	Office Contact _____

INSURANCE, MEDICARE OR MEDICAID INFORMATION	
Primary Insurance _____	Secondary Insurance (if applicable) _____
Policy # _____ Group _____	Policy # _____
Insurance Phone _____	Insurance Phone _____
Prescription Drug Coverage: Company _____	Phone _____
RXGRP# _____ RXBIN# _____	PCN/ID# (if available) _____

CLINICAL INFORMATION	
Primary Diagnosis: _____	ICD-10: _____
Current Therapies: <input type="checkbox"/> Antihistamines <input type="checkbox"/> β agonist (<input type="checkbox"/> Long-acting <input type="checkbox"/> Short-acting) <input type="checkbox"/> Corticosteroids (<input type="checkbox"/> Inhaled <input type="checkbox"/> Nasal <input type="checkbox"/> Oral) <input type="checkbox"/> Decongestants <input type="checkbox"/> Immunotherapy ___ months <input type="checkbox"/> Leukotriene modifiers <input type="checkbox"/> Other _____	
Previous Treatment: <input type="checkbox"/> Naïve <input type="checkbox"/> Restart <input type="checkbox"/> Continued therapy; date: _____	
Lab results: <input type="checkbox"/> History of positive skin OR RAST test to a perennial aeroallergen <input type="checkbox"/> Pretreatment serum IgE level _____ IU/mL; date _____ <input type="checkbox"/> Other _____ PLEASE ATTACH A LIST OF PATIENT'S CURRENT MEDICATIONS.	

DRUG NAME	DOSE/FREQUENCY	DIRECTIONS FOR USE	QTY	REFILLS
<input type="checkbox"/> Xolair for Asthma	150 mg vial	Every 4 weeks Dosing Interval: <input type="checkbox"/> Administer 150 mg subcutaneously every 4 weeks. <input type="checkbox"/> Administer 300 mg subcutaneously every 4 weeks. <input type="checkbox"/> Administer: _____ mg subcutaneously every 4 weeks. Every 2 weeks Dosing Interval: <input type="checkbox"/> Administer 225 mg subcutaneously every 2 weeks. <input type="checkbox"/> Administer 300 mg subcutaneously every 2 weeks. <input type="checkbox"/> Administer 375 mg subcutaneously every 2 weeks. <input type="checkbox"/> Administer: _____ mg subcutaneously every 2 weeks. <i>***Dose based on IgE level and weight. Please provide pertinent laboratory data.</i>	28-day supply	
<input type="checkbox"/> Xolair for CIU	150 mg vial	<input type="checkbox"/> Administer 150 mg subcutaneously every 4 weeks. <input type="checkbox"/> Administer 300 mg subcutaneously every 4 weeks.	28-day supply	
<input type="checkbox"/> Xolair Supplies		10 mL vial of sterile water for injection per doses for reconstitution Supply Kit consisting of: • Alcohol swabs • Flexible bandages 1" x 3" • 3 mL Luer Lock injection syringe • 18G x 1 1/2" needle for reconstitution • 25G x 5/8" needle for subcutaneous injection <input type="checkbox"/> No supplies (Supplies will be sent with shipment unless indicated.)		
<input type="checkbox"/> EpiPen		Use as directed.		
<input type="checkbox"/> EpiPen Jr.		Use as directed.		

Patient has received injection training Physician's office to provide injection training Benevere Rx to coordinate injection training

Deliver to: Patient's home MD's Office 1st dose to MD's Office, remaining refills to patient's home

Statement of Medical Necessity: I certify the prescribed therapy is medically necessary. I will be supervising the patient's treatment accordingly and all information is accurate to the best of my knowledge. I authorize Benevere as my designated agent and on behalf of my patient to (1) provide any information on this form to the insurer of the above name patient and to (2) forward the above prescription by fax or other mode of delivery to the pharmacy chosen by the above named patient.

Prescriber's Signature (signature required. NO STAMPS) _____ Date _____

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.